Saving Hearts and Lives in Advanced Prostate Cancer: Choosing Between ADT Agonists and Antagonists – Tweetorial Archive




Provided by Integrity Continuing Education, Inc.


Funding for this Independent Medical Education Grant is being provided from Pfizer Inc and Myovant Sciences Ltd.


Hormone-based intervention with androgen deprivation therapy has been the cornerstone of treatment for men with advanced prostate cancer (PCa) for decades, since the first gonadotropin-releasing hormone (GnRH) agonist was introduced in 1985. This critical advance remained the standard of care until the approval of the first GnRH antagonist in 2008. The GnRH antagonists, degarelix and oral relugolix, have an immediate onset of action with no associated testosterone surge. Additionally, GnRH antagonists have been associated with fewer adverse cardiovascular events, which prompted some genitourinary oncologists to call for a new standard of care for patients with PCa who have or are at high risk for cardiovascular disease. By participating in this activity, clinicians will gain a better understanding of the current landscape of PCa treatment with an emphasis on the most recent clinical data and approvals and best practices for promoting adherence to treatment.


Archana Ajmera, MSN, ANP-BC, AOCNP
APP Supervisor
Division of Hematology-Oncology
University of California at San Diego
San Diego, California


Rana R. McKay, MD (Co-Chair)
Associate Professor of Medicine
Co-Leader, Genitourinary Disease Team
Moores Cancer Center
University of California, San Diego
La Jolla, California


Alicia Morgans, MD, MPH
Member of the Faculty
Harvard Medical School
Medical Director, Survivorship Program
Dana-Farber Cancer Institute
Boston, Massachusetts


Brian I. Rini, MD, FASCO (Co-Chair)
Professor of Medicine
Chief of Clinical Trials
Vanderbilt Ingram Cancer Center
Nashville, Tennessee


Release date: March 17, 2022
Expiration date: March 17, 2023
Estimated time to complete activity: 45 minutes



This educational activity has been designed to meet the needs of urologists, medical oncologists, radiation oncologists, and other clinicians who treat men with advanced prostate cancer, including internal medicine physicians, physician assistants, and nurse practitioners who specialize in genitourinary oncology.


Upon completion of this educational activity, participants should be able to:

  • Select potential candidates with advanced PCa or treatment with GnRH antagonists
  • Elucidate the differences between GnRH agonists and antagonists in terms of mechanism and clinical effect
  • Outline cardiovascular risks or benefits inherent in currently available GnRH agonists and antagonists as evidenced by clinical trials and other analyses in medical literature
  • Implement a shared decision-making approach and other techniques that will enhance adherence with oral anti-cancer medications

There are no fees for participating and receiving CME credit for this activity. During the period of March 17, 2022 through March 17, 2023 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.




Physician Continuing Education

Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Archana Ajmera, MSN, ANP-BC, AOCNP
Advisory Boards: Bayer, Pfizer

Rana R. McKay, MD
Advisory Boards: AstraZeneca, Bayer, Bristol-Myers Squibb, Calithera, Caris Life Sciences, Dendreon, Exelixis, Johnson & Johnson, Merck, Myovant, Sanofi, Sorrento Therapeutics, Tempus
Research (Institution): Bayer, Tempus

Alicia Morgans, MD, MPH
Advisory Boards: AAA, Astellas, AstraZeneca, Bayer, Blue Earth, Clovis, Dendreon, Exelixis, Janssen, Myriad, Myovant, Novartis, Sanofi
Contracted Research: Astellas, Bayer, Dendreon, Myovant, Sanofi

Brian I. Rini, MD, FASCO
Consulting Fees: Alkermes, Aravive, Arrowhead Pharmaceuticals, Aveo, Bristol-Myers Squibb, Compugen, Corvus, Eisai, Genentech-Roche, GlaxoSmithKline, Merck, Pfizer, Shinonogi, Surface Oncology, Synthorx, 3DMedicines
Research Funding (Institution): Aravive, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Dragonfly Therapeutics, Exelixis, Genentech-Roche, GlaxoSmithKline, Hoffman-LaRoche, Immunomedics, Incyte, Merck, Mirati Therapeutics, Pfizer, Seattle Genetics, Surface Oncology, Taris
Stock: PTC Therapeutics

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc. you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Continue to Pretest